Harrow Health, Inc. (HROW)

NASDAQ: HROW · IEX Real-Time Price · USD
21.32
+0.52 (2.52%)
Mar 30, 2023, 10:32 AM EDT - Market open
2.52%
Market Cap 637.71M
Revenue (ttm) 88.60M
Net Income (ttm) -14.09M
Shares Out 29.97M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 79,016
Open 21.00
Previous Close 20.80
Day's Range 20.95 - 21.67
52-Week Range 5.40 - 22.35
Beta 0.16
Analysts Buy
Price Target 23.26 (+9.1%)
Earnings Date May 4, 2023

About HROW

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commerc... [Read more]

Sector Healthcare
Founded 1998
Employees 182
Stock Exchange NASDAQ
Ticker Symbol HROW
Full Company Profile

Financial Performance

In 2022, Harrow Health's revenue was $88.60 million, an increase of 22.24% compared to the previous year's $72.48 million. Losses were -$14.09 million, -23.77% less than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for HROW stock is "Buy." The 12-month stock price forecast is $23.26, which is an increase of 9.10% from the latest price.

Price Target
$23.26
(9.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 day ago - Zacks Investment Research

B. Riley Leads Financing to Support Harrow Health Acquisition

LOS ANGELES , March 28, 2023 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B.

Other symbols: RILY
1 day ago - PRNewsWire

Harrow Announces New $100 Million Secured Credit Facility with Oaktree

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agre...

2 days ago - Business Wire

HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

NEW YORK , March 25, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc.  ("Harrow Health" or the "Company"...

5 days ago - PRNewsWire

Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022. The ...

6 days ago - Business Wire

HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

NEW YORK , March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company")...

1 week ago - PRNewsWire

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

NEW YORK , March 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. ...

1 week ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow Health, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to ...

2 weeks ago - PRNewsWire

Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved ...

2 weeks ago - Business Wire

HARROW HEALTH SHAREHOLDER ACTION REMINDER : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

NEW YORK , March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc.  ("Harrow Health" or the "Company"...

2 weeks ago - PRNewsWire

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

NEW YORK , March 10, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. ...

2 weeks ago - PRNewsWire

Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory...

3 weeks ago - Business Wire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

NEW YORK , March 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (...

3 weeks ago - PRNewsWire

Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and...

1 month ago - Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow Health...

1 month ago - Accesswire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Compan...

1 month ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

BENSALEM, Pa. , Feb. 25, 2023 /PRNewswire/ -- ­Law Offices of Howard G.

1 month ago - PRNewsWire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Harrow Health, In...

1 month ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investors concerning the Company's...

1 month ago - Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) on behalf of investors concerning the Compan...

1 month ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $HROW #HROW--The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc.

1 month ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $HROW #HROW--The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc.

1 month ago - Business Wire

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: H...

1 month ago - Business Wire

Harrow Launches Next-Generation Compounded Atropine Formulations

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compounded Atropine...

1 month ago - Business Wire

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanen...

2 months ago - Business Wire